CDX
MM.1R
Tumor indication
Lymphoid
Tumor subtype
Multiple Myeloma
Description
MM.1R (Multiple Myeloma CDX Model)
The MM.1R multiple myeloma line was derived from a patient with plasma cell leukemia. It is resistant to glucocorticoids, making it useful in resistance mechanism studies. MM.1R retains features of malignant plasma cells, including immunoglobulin secretion. Its reproducibility supports hematology drug development pipelines.
Key Features:
- Derived from plasma cell leukemia.
- Glucocorticoid-resistant line.
- Produces immunoglobulin light chains.
- Tumorigenic in xenograft systems.
Applications:
MM.1R is used in multiple myeloma resistance studies. It supports evaluation of therapies targeting glucocorticoid-resistant disease. Researchers use it to identify biomarkers and novel therapeutic strategies. Its biology makes it critical in advanced hematology research.
Details
- Tumor indication
- Lymphoid
- Tumor subtype
- Multiple Myeloma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- RNA-Seq, WES
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.